Macintosh HD:Users:trkim:Desktop:SERVER BACKUP:2020:Marketing:20201028-37-Graphic-for-News-Release-Template:News-Release-Template.jpg, Picture

CONTACT:

Allison Peters 
allison.peters@luhs.org
708-216-5500

 

MAYWOOD, IL – According to new research from Loyola University Chicago Stritch School of Medicine, the number of metabolic and bariatric surgery procedures performed in the United States fell below 200,000 in 2024 for the first time since 2020, representing a decline of more than 20% from the previous year.

Researchers based their estimates on data from the American College of Surgeons Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program (ACS-MBSAQIP), which includes reported outcomes from accredited bariatric surgery centers nationwide.

New research highlights shifting obesity treatment trends in the U.S.

“After years of steady growth, the number of metabolic and bariatric procedures in the U.S. is experiencing a decline amid persistently high obesity rates and a surge in the use of GLP-1 medications,” said lead study author Tyler Cohn, MD, director of Metabolic and Bariatric Surgery at Loyola Medicine. “While we did not study causation, the concern is that many patients are selecting non-surgical therapies for obesity without fully understanding all of their available options. Millions more are living with obesity and are not receiving treatment at all.”

While GLP-1 medications have emerged as effective treatment options for many individuals seeking to lose weight, experts caution that they are not the right fit for everyone. Some patients experience side effects, achieve limited results or require a more comprehensive solution to address severe obesity and related health conditions.

Matching patients with the right weight loss treatment 

For patients like Jakhya Chandler, bariatric surgery proved to be the life-changing treatment she needed.

Chandler first came to Loyola Medicine seeking treatment for a hernia. During her evaluation, physicians recommended she lose at least 20 pounds, a goal she recalled feeling nearly impossible to achieve on her own. She had previously tried a GLP-1 medication but saw minimal weight loss and limited success.

After being referred to Loyola's bariatric program, Chandler met with Kevin Brown, MD, a bariatric surgeon at Loyola.

"He said that the older I get, the more weight I gain, the more health complications I will have," Chandler said. "That really stuck with me."

Following five months of preparation, including nutrition counseling and psychiatric counseling, Chandler underwent a laparoscopic sleeve gastrectomy in June 2025. Since surgery, she has lost more than 100 pounds and experienced significant improvements in her overall health and quality of life.

Bariatric surgery remains an effective treatment for severe obesity

Patients who remain on high-dose GLP-1 medications long-term can achieve an average total body weight loss of up to 25%. However, among all patients who begin these medications, average weight loss is 10% of total body weight.

Despite the proven effectiveness of bariatric surgery, fewer than 1% of eligible patients undergo a metabolic or bariatric procedure in any given year, according to the American Society for Metabolic and Bariatric Surgery.

Today, approximately 42% of U.S. adults live with obesity, and nearly 10% have severe obesity. Metabolic and bariatric surgery, including gastric bypass and sleeve gastrectomy, remains the most effective and durable treatment for severe obesity and can improve or resolve conditions such as Type 2 diabetes, heart disease and high blood pressure.

The Loyola Center for Metabolic Surgery & Bariatric Care offers a comprehensive, multidisciplinary approach that includes behavioral health services, registered dietitian support, medical weight management, endoscopic therapies and bariatric surgery, helping patients find the treatment strategy that works best for them.